Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin AVitamin A (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Loading...

Supplementary Data — Vitamin A for COVID-19: real-time meta analysis of 17 studies (13 treatment studies and 4 sufficiency studies)

@CovidAnalysis, September 2023
https://c19early.org/vameta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Rohani (DB RCT) 26% 0.74 [0.31-1.76] hosp. 8/89 11/91 Rohani (DB RCT) 32% 0.68 [0.20-2.33] no recov. 4/89 6/91 Rohani (DB RCT) 80% 0.20 [0.05-0.91] no recov. 2/89 10/91 Rohani (DB RCT) 87% 0.13 [0.03-0.61] no recov. 1/89 8/91 Rohani (DB RCT) 49% 0.51 [0.13-1.98] no recov. 3/89 6/91 Rohani (DB RCT) 63% 0.37 [0.12-1.12] no recov. 4/89 11/91 Rohani (DB RCT) 20% 0.80 [0.31-2.04] no recov. 7/89 9/91 Rohani (DB RCT) 40% 0.60 [0.25-1.45] no recov. 7/89 12/91 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] death 0/30 4/30 ICU patients CT​1 Beigm.. (SB RCT) 41% 0.59 [0.17-1.28] hosp. 4/30 16/30 ICU patients CT​1 Beigm.. (SB RCT) 45% 0.55 [0.38-0.78] SOFA 30 (n) 30 (n) ICU patients CT​1 Elkazzaz (RCT) 86% 0.14 [0.01-2.60] death 0/20 3/20 Elkazzaz (RCT) 67% 0.33 [0.08-1.46] ICU 2/20 6/20 Elkazzaz (RCT) 35% 0.65 [0.55-0.76] recov. time 20 (n) 20 (n) Elkazzaz (RCT) 44% 0.56 [0.48-0.65] viral time 20 (n) 20 (n) Somi (RCT) -50% 1.50 [0.29-7.73] death 3/15 2/15 Somi (RCT) 0% 1.00 [0.24-4.18] ventilation 3/15 3/15 Somi (RCT) 25% 0.75 [0.20-2.79] ICU 3/15 4/15 Somi (RCT) -76% 1.76 [0.73-4.26] no improv. 15 (n) 15 (n) Somi (RCT) -8% 1.08 [0.87-1.34] hosp. time 15 (n) 15 (n) Doocy 26% 0.74 [0.11-4.80] death 1/8 23/136 Chung (RCT) 75% 0.25 [0.06-0.99] PASC 9 (n) 8 (n) LONG COVID Chung (RCT) 68% 0.32 [0.01-6.90] PASC 0/9 1/8 LONG COVID Chung (RCT) 70% 0.30 [0.04-2.31] PASC 1/9 3/8 LONG COVID Chung (RCT) 75% 0.25 [0.07-0.89] PASC 2/9 7/8 LONG COVID Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 COVIDENCE UK Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Nimer 21% 0.79 [0.45-1.35] hosp. 15/144 204/2,004 Nimer 21% 0.79 [0.46-1.30] severe case 17/144 243/2,004 Vaisi 17% 0.83 [0.48-1.00] hosp. 1,140 (n) 2,815 (n) Vaisi 11% 0.89 [0.69-0.98] symp. case 1,140 (n) 2,815 (n) Vitamin A COVID-19 outcomes c19early.org Sep 2023 1 CT: study uses combined treatment Favors vitamin A Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit